The duration of effect in patients with osteoarthritis has been demonstrated to be up to 12 months.
RenehaVis™ can be used for grades 1, 2A and 2B. RenehaVis™ has not been approved for grade 3 knee OA.
RenehaVis™ has been approved for use up to 3 times, once a week. Any usage of RV out of this scope will be at the physician’s discretion.
There has been no proven clinical evidence on the safety and efficacy of concomitant administration of hyaluronic acid (HA) with other intra-articular products.
Other systemic therapies such as pain relief medication, local anaesthetics, corticosteroids, PRP or shock wave therapies do not interfere with the administration of hyaluronic acid (HA).
The first chamber of RenehaVis™ contains: 2.2% of HA of an average molecular weight of 1 million Daltons.
The second chamber of RenehaVis™ contains: 1.0% of HA of an average molecular weight of 2 million Daltons.
RenehaVis™ is from the fermentation of bacteria – the manufacturing process of RenehaVis™ is covered by a patent as it is a process. The manufacturing process ensures the strictest level of purification and does not use any products from animals or of animal origins.
The use of RenehaVis™ at other joints have not been approved. Using it at other joints will be an off-label prescription and is at discretion of doctor.
RenehaVis™ has a CE certificate since Feb 2009 and is approved to be marketed in the EEC. Countries outside the EEC might have to undergo a registration or notification process, dependent on the location.